November 17, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.11.009

Glucagon-like peptide-1 receptor agonist use and overall survival in endometrial cancer: a multicenter propensity score-matched cohort study.

Listen to this summary

This retrospective TriNetX cohort study asked whether GLP-1 receptor agonist use is associated with lower 5-year all-cause mortality in women with endometrial cancer. After propensity score matching and a 2-year landmark analysis anchored to diagnosis date, GLP-1RA users showed no significant survival benefit compared with non-users (primary HR 0.81, 95% CI 0.65-1.02; landmark HR 0.92, 95% CI 0.63-1.34), and results held against DPP-4 inhibitor users. The apparent protective effect (HR 0.58) seen when comparing against women who never used GLP-1RAs disappeared once follow-up was anchored to diagnosis, suggesting the earlier association may reflect study design bias rather than a true effect.

Abdelrahman Yousif, Mohanad Elchouemi, Arsalaan B Asad

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play